infants – Lab DB

Pharmaceutical R&D

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

Teuku Ryan Jul 1, 2026 0

Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…

European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

YOU MAY HAVE MISSED

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286

Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition

Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation